2023-08-14 09:41:38 ET
- Armata Pharmaceuticals press release ( NYSE: ARMP ): Q2 GAAP EPS of -$0.17.
- Revenue of $0.98M (-47.9% Y/Y).
For further details see:
Armata Pharmaceuticals GAAP EPS of -$0.17, revenue of $0.98M2023-08-14 09:41:38 ET
For further details see:
Armata Pharmaceuticals GAAP EPS of -$0.17, revenue of $0.98MMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Armata Pharmaceuticals Inc. Company Name:
ARMP Stock Symbol:
Market:
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update PR Newswire LOS ANGELES , May 7, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high...
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update PR Newswire LOS ANGELES , March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology com...
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva PR Newswire Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 20...